DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on this evidence associated with miRNAs, an Argentinean study proposed a new pharmacogenomic tool to better identify CML LSCs by exploring, with next-generation sequencing (NGS) technology, the profile of the miRNoma of CD26+ LSCs and HSCs.